Cibc Asset Management Inc Biomarin Pharmaceutical Inc Transaction History

Cibc Asset Management Inc

  • $29.6 Billion
  • Q2 2025

A detailed history of Cibc Asset Management Inc transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Cibc Asset Management Inc holds 8,143 shares of BMRN stock, worth $428,891. This represents 0.0% of its overall portfolio holdings.

Number of Shares
8,143
Previous 8,090 0.66%
Holding current value
$428,891
Previous $571,000 21.72%
% of portfolio
0.0%
Previous 0.0%

Shares

32 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 14, 2025
BUY
$54.08 - $68.32 $2,866 - $3,620
53 Added 0.66%
8,143 $447,000
Q1 2025

May 13, 2025
BUY
$61.25 - $72.83 $26,521 - $31,535
433 Added 5.65%
8,090 $571,000
Q4 2024

Jan 31, 2025
BUY
$61.93 - $70.49 $57,347 - $65,273
926 Added 13.76%
7,657 $503,000
Q3 2024

Nov 06, 2024
BUY
$69.02 - $93.84 $24,778 - $33,688
359 Added 5.63%
6,731 $473,000
Q2 2024

Aug 01, 2024
BUY
$74.43 - $92.22 $24,189 - $29,971
325 Added 5.37%
6,372 $524,000
Q1 2024

May 09, 2024
BUY
$83.81 - $99.0 $1,089 - $1,287
13 Added 0.22%
6,047 $528,000
Q4 2023

Feb 13, 2024
SELL
$76.22 - $98.51 $33,917 - $43,836
-445 Reduced 6.87%
6,034 $581,000
Q3 2023

Oct 30, 2023
BUY
$85.07 - $94.48 $13,185 - $14,644
155 Added 2.45%
6,479 $573,000
Q2 2023

Aug 14, 2023
BUY
$86.68 - $100.3 $346 - $401
4 Added 0.06%
6,324 $548,000
Q1 2023

May 12, 2023
BUY
$87.74 - $117.27 $27,287 - $36,470
311 Added 5.18%
6,320 $614,000
Q4 2022

Feb 13, 2023
SELL
$80.93 - $108.63 $180,716 - $242,570
-2,233 Reduced 27.09%
6,009 $621,000
Q3 2022

Nov 03, 2022
BUY
$82.16 - $96.94 $1,807 - $2,132
22 Added 0.27%
8,242 $699,000
Q2 2022

Aug 09, 2022
SELL
$71.48 - $86.85 $255,112 - $309,967
-3,569 Reduced 30.27%
8,220 $681,000
Q1 2022

May 06, 2022
SELL
$74.28 - $92.69 $2.14 Million - $2.67 Million
-28,805 Reduced 70.96%
11,789 $909,000
Q4 2021

Feb 08, 2022
BUY
$71.72 - $91.47 $65,982 - $84,152
920 Added 2.32%
40,594 $3.59 Million
Q3 2021

Nov 09, 2021
BUY
$74.77 - $85.47 $475,985 - $544,102
6,366 Added 19.11%
39,674 $3.07 Million
Q2 2021

Aug 16, 2021
BUY
$75.51 - $84.79 $262,472 - $294,730
3,476 Added 11.65%
33,308 $2.78 Million
Q1 2021

May 14, 2021
BUY
$74.73 - $90.69 $1.73 Million - $2.1 Million
23,128 Added 344.99%
29,832 $2.25 Million
Q4 2020

Feb 03, 2021
SELL
$72.61 - $90.2 $887,439 - $1.1 Million
-12,222 Reduced 64.58%
6,704 $588,000
Q3 2020

Nov 05, 2020
BUY
$71.87 - $131.03 $73,019 - $133,126
1,016 Added 5.67%
18,926 $1.44 Million
Q2 2020

Jul 28, 2020
BUY
$79.55 - $124.22 $56,321 - $87,947
708 Added 4.12%
17,910 $2.21 Million
Q1 2020

Apr 30, 2020
SELL
$71.37 - $96.85 $3.65 Million - $4.95 Million
-51,100 Reduced 74.81%
17,202 $1.45 Million
Q4 2019

Feb 14, 2020
BUY
$64.27 - $86.37 $3.32 Million - $4.46 Million
51,687 Added 311.09%
68,302 $5.78 Million
Q3 2019

Oct 30, 2019
SELL
$67.4 - $85.11 $27,364 - $34,554
-406 Reduced 2.39%
16,615 $1.12 Million
Q2 2019

Aug 05, 2019
BUY
$80.35 - $93.9 $47,486 - $55,494
591 Added 3.6%
17,021 $1.46 Million
Q1 2019

May 06, 2019
SELL
$84.2 - $98.62 $27,954 - $32,741
-332 Reduced 1.98%
16,430 $1.46 Million
Q4 2018

Feb 12, 2019
BUY
$80.14 - $106.07 $45,519 - $60,247
568 Added 3.51%
16,762 $1.43 Million
Q3 2018

Nov 02, 2018
BUY
$93.92 - $105.72 $31,932 - $35,944
340 Added 2.14%
16,194 $1.57 Million
Q2 2018

Aug 09, 2018
BUY
$76.01 - $99.03 $74,945 - $97,643
986 Added 6.63%
15,854 $1.49 Million
Q1 2018

Apr 30, 2018
BUY
$77.67 - $92.63 $12,038 - $14,357
155 Added 1.05%
14,868 $1.21 Million
Q4 2017

Feb 02, 2018
BUY
$80.76 - $95.13 $109,591 - $129,091
1,357 Added 10.16%
14,713 $1.31 Million
Q3 2017

Nov 06, 2017
BUY
$80.6 - $94.95 $1.08 Million - $1.27 Million
13,356
13,356 $1.24 Million

Others Institutions Holding BMRN

# of Institutions
689
Shares Held
187M
Call Options Held
1.31M
Put Options Held
1.1M
View Full List

About BIOMARIN PHARMACEUTICAL INC

BMRN Quotes by TradingView
  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $9.79B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Cibc Asset Management Inc Portfolio

Follow Cibc Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cibc Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Cibc Asset Management Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email